News

Moscow, Russia, July 25, 2017 – InSysBio LLC (www.insysbio.ru), one of the pioneers in Quantitative Systems Pharmacology (QSP) modeling and simulation for drug development, announced today a renewal of multi-year Master Service Agreement with ASTEX Pharmaceuticals, Inc.

Moscow, Russia, July 14, 2017. The scientists from BIND RUS and InSysBio (www.insysbio.ru) published a joint research of the new class of anti-oncology treatment in the Journal of Controlled Release. Unique nanoparticles enriched with medications can deliver its content targeted to the tumor site, and the parameters of their effectiveness are programmed during the forming phase.

Moscow, Russia - 21 June, 2017. InSysBio scientific group led by Tatiana Karelina developed a quantitative system pharmacology model of Alzheimer’s disease. First part published in CPT PSP shows how to design initial phases of clinical trials of new drugs and to interpret the data obtained.

20-22 February 2017 the 10th ISBM Enclosed Conference was held. For ten years the employees annually have been meeting together to share their scientific results and talk over future plans. ISBM did a great job in this working year.

Moscow, Russia - February 2, 2017. Institute for Systems Biology Moscow (ISBM) announced the recent update of the Immune Response Template (IRT) platform and its online demo. The project aimed to integrate and visualize available data on immune cells, cytokine, chemokines and other mediators interactions in human. IRT is a unique tool due to its focus on quantitative systems pharmacology (QSP) modeling. Using the platform modelers in pharmaceutical companies can strongly improve the drug R&D process.

Moscow, Russia - December 20, 2016. Oleg Demin, CEO of the Institute for Systems Biology Moscow, gave a talk at the seminar "Big data and decision support systems for pharmaceuticals.".